Cardinal Health (CAH) Q1 2025 Earnings Transcript

Cardinal Health reported a strong Q1 with revenue of $52 billion, operating earnings up 12% to $625 million, and EPS up 9% to $1.88, while raising fiscal 2025 EPS guidance to $7.75-$7.90 and adjusted free cash flow outlook to $1.0 billion-$1.5 billion. Pharma and Specialty Solutions was the main driver, with segment profit up 16% to $530 million and revenue up 16% excluding the customer transition, while GMPD guidance was cut to $140 million-$175 million amid health and welfare cost pressure and higher manufacturing expenses. The company also announced a $1.1 billion acquisition of Integrated Oncology Network and reiterated that tariffs, Moly-99 shortages, and hurricane-related disruptions create near-term supply-chain risk.

Analysis

The key signal is not the headline beat, but the quality of the beat: Cardinal is showing it can rebase its earnings power higher even while absorbing a large customer transition. That matters because the market has likely been treating the transition as a one-off drag; the company is now demonstrating offsetting levers in mix, service, and simplification that should persist for multiple quarters. The bigger second-order effect is that Pharma’s stronger economics reduce the need to lean on lower-quality volume elsewhere, which should improve incremental margins as the new customer base fully ramps.

The underappreciated setup is in the guidance cadence. Q2 likely looks messy because COVID timing, Moly-99 shortages, and GMPD health-and-welfare reset all hit together, but that creates a cleaner back-half setup than the stock may be pricing. If management executes even modestly on the GMPD turnaround, the business has multiple levers to re-accelerate into FY26, and the announced oncology acquisition adds a strategic call option on higher-multiple specialty exposure without stressing leverage.

The contrarian risk is that investors over-earn this quarter’s enthusiasm into a smooth straight-line model. GMPD is still a weak spot, and tariff pass-through plus domestic manufacturing startup costs can erode the margin bridge if inflation accelerates faster than pricing. Also, the COVID and GLP-1 tailwinds are top-line helpful but not durable profit drivers, so any deceleration in broad pharma utilization would expose how much of the raise is timing versus true run-rate improvement.

Key Decisions for Investors

• Go long CAH on any post-earnings consolidation; target a 3-6 month hold. Upside is driven by a higher FY25 earnings base and improving confidence in FY26 leverage to the $300M GMPD target; downside is capped near-term by raised guidance and buybacks.
• Use a pair trade: long CAH / short a lower-quality medical-products distributor or supply-chain name with less specialty mix and more tariff exposure. The thesis is that CAH’s mix shift and service execution should outperform peers if pricing pressure intensifies.
• Buy CAH Jan-2026 $90 calls on weakness. Risk/reward is attractive if the market starts capitalizing the Specialty and simplification story at a higher multiple, while the premium is supported by cash flow and buybacks.
• If you already own CAH, hedge the Q2 volatility window with a short-dated collar into the next print. Q2 has multiple known headwinds that could create a temporary drawdown even if the full-year thesis remains intact.
• Monitor GEHC as a secondary beneficiary of stronger nuclear/diagnostic imaging volumes; a resumption in Moly-99 supply into Q3-Q4 should be constructive for imaging workflows, though the trade is lower conviction than CAH.